Table 2. Standardized incidence ratios (SIR) for all cancers according to gender, age at CHD diagnosis, and follow-up period.

	Total		Male		Female
Characteristics	O/E	SIR (95% CI)	O/E	SIR (95% CI)	O/E	SIR (95% CI)
All cancers	187/129.29	1.45 (1.25–1.67)	82/56.13	1.46 (1.16–1.81)	105/73.16	1.44 (1.17–1.74)
Age at CHD diagnosis, years
0–5	34/19.33	1.79 (1.22–2.46)	14/10.28	1.36 (0.74–2.28)	20/9.05	2.21 (1.35–3.41)
6–17	5/3.23	1.55 (0.50–3.62)	1/1.71	0.59 (0.01–3.26)	4/1.52	2.64 (0.71–6.75)
18–44	47/26.39	1.78 (1.31–2.37)	16/7.71	2.08 (1.19–3.37)	31/18.68	1.66 (1.13–2.36)
45–64	76/50.03	1.52 (1.20–1.90)	36/21.07	1.71 (1.20–2.37)	40/28.96	1.38 (0.99–1.88)
≥ 65	25/30.31	0.82 (0.53–1.22)	15/15.36	0.98 (0.55–1.61)	10/14.95	0.67 (0.32–1.23)
Follow-up period, years
< 1	26/28.68	0.85 (0.55–1.24)	9/12.89	0.65 (0.30–1.23)	17/15.79	1.01 (0.59–1.62)
1–2	70/44.92	1.51 (1.18–1.91)	34/19.78	1.66 (1.15–2.33)	36/25.17	1.39 (0.98–1.93)
≥ 3	91/55.69	1.63 (1.32–2.01)	39/23.47	1.66 (1.18–2.27)	52/32.21	1.61 (1.21–2.12)

Abbreviations: CI, confidence interval; E, expected case number; O, observed case number; SIR, standardized incidence ratio